There was no difference in the immunostaining for CD3 (median IHC score of 4 in both groups, p > 0.05, Fig. 3a), FOXP3 (positive staining in 13.8% and 15.7%, respectively, Fig. 3b) and PD-L1 (positive staining in 6.0% and 6.7%, respectively, Fig. 3d) in tumors from patients with metastatic disease compared to tumors from patients with non-metastatic disease. Here, FOXP3 is linked to metastatic neoplasm.